Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
17 hedge funds and large institutions have $230K invested in Titan Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
6% more funds holding
Funds holding: 16 → 17 (+1)
3.95% more ownership
Funds ownership: 0.33% → 4.28% (+3.9%)
44% less capital invested
Capital invested by funds: $408K → $230K (-$178K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4K |
| 2 |
MA
MCF Advisors
Covington,
Kentucky
|
+$1.16K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$56 |
| 4 |
Morgan Stanley
New York
|
+$21 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$56K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$29K |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.08K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BlackRock
New York
| – | -$25 | -3 | Closed |
|
|
NFSG
27
Newbridge Financial Services Group
Boca Raton,
Florida
| – | -$1 | – | – |
|
28
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$2 | – | – |
|
TTNP Hedge Fund Activity: Q1 2024 in Review
17 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2024, worth a combined $230K — down 44% from $408K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TTNP positions and 9 closed out — a net gain of 1 holder — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $4K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $56K sold.
- 17 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2024, up from 16 in Q4 2023.
- Funds reported $230K of Titan Pharmaceuticals stock for Q1 2024, down 44% quarter-over-quarter.
- 10 funds opened new Titan Pharmaceuticals positions in Q1 2024 and 9 closed out, a net change of +1 holder.
- The largest Titan Pharmaceuticals buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $4K added.
- The largest Titan Pharmaceuticals seller in Q1 2024 was Renaissance Technologies, an estimated $56K sold.
Based on aggregated 13F filings for Q1 2024.